RESULTS	Benefit from intensive , compared with moderate , statin therapy was significantly greater in the 59 % of the cohort who were carriers ( hazard ratio [ HR ] 0.59 , 95 % confidence interval [ CI ] 0.45 to 0.77 ) than in those who were noncarriers ( HR 0.94 , 95 % CI 0.70 to 1.27 ; p = 0.018 for interaction between 719Arg carrier status and treatment ) .\